What is altretamine used for?
Pharmaceutical Product Monograph: Altretamine (50 mg Capsules)
In the pharmaceutical industry, Altretamine (formerly known as Hexamethylmelamine) is a unique, orally active Antineoplastic Agent belonging to the methylmelamine class. As a pharmacist and manufacturer, I view this molecule as a “Second-Line Specialist”—it is technically designed for patients who have already undergone standard platinum-based chemotherapy but whose disease has persisted or recurred.
At your WHO-GMP facility in Mumbai, Altretamine (Hexalen equivalent) is a specialized Oncology SKU. Its primary value lies in its lack of complete cross-resistance with other alkylating agents, making it a critical “salvage” therapy in gynecological oncology.
Therapeutic Profile: Primary Indications
Altretamine is indicated as a single agent for the palliative treatment of specific cancers.
| Indication | Clinical Context | Technical Rationale |
| Recurrent Ovarian Cancer | Palliative Care | Gold Standard: Used when ovarian cancer has failed to respond to first-line therapy with Cisplatin and/or other alkylating agent combinations. |
| Persistent Ovarian Cancer | Post-First Line | Indicated for patients with persistent disease following initial surgical and chemotherapeutic debulking. |
| Off-Label / Research | Other Malignancies | Occasionally studied in clinical trials for small cell lung cancer or lymphomas, though not its primary FDA-approved indication. |
Mechanism: The “Stealth” Alkylating Agent
The precise mechanism of Altretamine is technically complex and not fully understood, but it is categorized as a “miscellaneous” alkylating agent:
Liver Activation: Altretamine is a prodrug. It must be activated in the liver by Cytochrome P450 (CYP1A2) enzymes.
Reactive Intermediates: It is N-demethylated to form Methylol intermediates (like pentamethylmelamine).
DNA Adducts: These reactive metabolites form covalent bonds (adducts) with DNA and other macromolecules. This technically leads to inter-strand and intra-strand DNA cross-linking.
Cytotoxicity: By damaging the DNA template, it prevents replication and transcription, eventually triggering apoptosis (cell death) in rapidly dividing cancer cells.
The Pharmacist’s “Technical Warning”
The “Neuro-Heme” Boxed Warning: As a pharmacist, I must emphasize the two primary toxicities: Neurotoxicity (peripheral neuropathy, agitation, hallucinations) and Hematologic suppression (low white cells and platelets). Regular neurological exams and monthly blood counts are technically mandatory.
The “MAOI” Interaction: A critical B2B safety concern: Taking Altretamine with MAO Inhibitors (certain antidepressants) can lead to severe, life-threatening hypotension.
Dosing Schedule: It is typically given in a 28-day cycle (taking capsules for 14 or 21 days followed by a rest period). To reduce nausea, it should technically be taken after meals and at bedtime, divided into 4 doses.
Vesicant Handling: While oral, the drug is still cytotoxic. Caregivers should wear gloves when handling the capsules to avoid accidental exposure.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Solubility & pH” USP: Altretamine is practically insoluble in water but becomes more soluble at pH 3.0 or below. On your digital marketplace, highlight your Precision Micronization and Formulation that ensures consistent gastric dissolution and rapid absorption ($T_{max}$ of 2–4 hours).
The “Maintenance” Market: For international B2B oncology tenders, market Altretamine as a “Low-Toxicity Maintenance Option” for patients who cannot tolerate further IV chemotherapy. Its oral route is a major technical advantage for home-based palliative care.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Altretamine 50 mg capsules to support your registration in international B2B oncology tenders for specialized cancer hospitals.